Is XLRN stock a buy after the volume spike?

The volume spike suggests a short-term bounce opportunity, not a guaranteed buy. Use tight stops and consider staged entries near USD 176.00–178.00. Confirm with clinical news and sector flows before increasing exposure.

What are realistic XLRN stock price targets?

Conservative target is USD 200.00, a base target is USD 250.00, and Meyka AI yearly forecast is USD 324.19. These imply upside of 11.88%, 39.86%, and 81.30% respectively from USD 178.75.

How does Meyka AI rate XLRN stock?

Meyka AI rates XLRN with a score out of 100: 66.64, Grade B, Suggestion HOLD. The grade factors in benchmark and sector comparisons, key metrics, financial growth, forecasts, and analyst consensus.

Which indicators confirm the oversold bounce in XLRN stock?

High relative volume of 6.23 and a rebound off intraday lows are early signals. Price above the 50-day average supports a mean-reversion trade. RSI was not available in the feed, so use volume and moving averages for confirmation.

US Stocks

XLRN Acceleron Pharma Inc. (NASDAQ) 27 Feb 2026: Oversold bounce setup

ByHuzaifa Zahoor February 28, 2026

XLRN stock appears set for a short-term rebound after a volume surge and a sharp intraday swing. Acceleron Pharma Inc. (NASDAQ) closed at USD 178.75 on 27 Feb 2026 with 7,884,284 shares traded, well above the 50-day average. The big relative volume of 6.23 suggests short-term selling pressure may have exhausted itself, creating an oversold bounce opportunity for active traders and tactical investors.